SEC Filing Summary: ChromaDex Corporation (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on February 11, 2015. The report serves as a current disclosure pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The filing primarily functions to disseminate a press release (Exhibit 99.1) issued on the same date.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to announce the release of a press statement rather than a financial report containing quantitative data.
Material Changes
No material financial changes or comparative period data are disclosed within the text of this Form 8-K. The filing references the attached press release for details regarding the event being reported.
Guidance, Outlook, and Risks
The filing includes a standard Regulation FD disclosure (Item 7.01) and categorizes the press release under "Other Events" (Item 8.01). The document explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are detailed in the body of this report.
Key Facts for Investor Verification
- Verify the content of the attached press release (Exhibit 99.1) to understand the specific event triggering this filing.
- Note that the registrant is ChromaDex Corporation, not "Niagen Bioscience, Inc." as indicated in the request metadata.
- Confirm that this filing does not contain audited financial statements or updated financial metrics.
- Review the signature block confirming Frank L. Jaksch, Jr. as the Chief Executive Officer authorizing the report.